News | June 20, 2012

SNM's Position on Dose Optimization


June 20, 2012 — In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.

The Society of Nuclear Medicine (SNM) and the SNM Technologist Section (SNMTS) recognize that the use of low levels of radiation in these procedures entails some possible risk. Radiation dose for all nuclear medicine and molecular imaging procedures should be optimized so that the patient receives the smallest possible amount of radiopharmaceutical that will provide the appropriate diagnostic information. SNM and SNMTS also recognize that if an appropriate procedure—one that can provide the physician with clinical information essential to the patient’s treatment—is not performed when necessary due to fear of radiation, it can be detrimental to the patient.

The SNM and SNMTS believe that the right test with the right dose should be given to the right patient at the right time. When nuclear medicine and molecular imaging procedures are performed correctly on appropriate patients, the benefits of the procedure far outweigh the potential risks. The procedure that provides the most useful clinical information is the one that should be performed.

To ensure the appropriate use of these procedures, all nuclear medicine facilities should have comprehensive quality control measures in place, their nuclear medicine physicians should have up-to-date training, and their technologists should be appropriately trained and certified. SNM and SNMTS and their members continually strive to improve quality and standards to ensure patients receive the best, safest and most appropriate care.

For more information: www.snm.org

 

 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now